BioPharma Drug Discovery

The field of biopharmaceutical drug discovery relies on advanced analytical and cell-based technologies that enable researchers to understand complex biological systems, identify novel therapeutic targets, and develop safer, more effective treatments. Modern drug discovery workflows integrate live-cell imaging, microfluidic screening, and real-time kinetic analysis to bridge the gap between cellular behavior and molecular interactions.

Within this category, Altium International offers a connected portfolio of instruments that support every stage of discovery, from single-cell behavior to molecular interaction analysis.

The HoloMonitor® from Phase Holographic Imaging provides label-free live-cell imaging to track cell growth, morphology, and response to compounds in real time, offering insight into cellular health and drug efficacy without disturbing natural cell function.

For functional screening and antibody discovery, DPBio’s CytoSpark® CSP and OMNIdrop platforms use droplet microfluidics to encapsulate and analyze millions of single cells in parallel. This approach enables rapid identification of high-performing clones, antibodies, or enzymes while reducing cost and time compared to traditional methods.

At the molecular level, Surface Plasmon Resonance Microscopy (SPRM) from Biosensing Instrument US measures binding kinetics directly on living cells, providing real-time, label-free insights into receptor–ligand and antibody–antigen interactions that are critical for drug characterization.

Together, these technologies form a powerful framework for BioPharma Drug Discovery, helping researchers bridge the gap between cellular behavior and molecular function to advance the next generation of targeted therapies.